UK‑based Ananda Pharma is advancing MRX‑1 to treat endometriosis‑associated pain, signalling a shift toward regulated cannabinoid medicines backed by clinical trials.

Legal cannabis in Africa is booming, but traditional rural growers face exclusion from a system dominated by capital, regulation, and global investors.

A cannabis-derived drug, DKJ127, eased chronic back pain in a large trial, offering hope as a safer alternative to opioids.

Despite voter approval, Nebraska’s draft medical cannabis rules could restrict access and contradict the 2024 ballot’s patient-first intentions.

Trump’s Medicare CBD pitch reframes the cannabis rescheduling debate in senior health and cost-savings terms

A negligence claim over an acequia flood could reshape cannabis risk management

Releaf brings its UK tech-led medical cannabis model to Germany, aiming to expand patient access through AI triage, compliance, and doctor-led care.

As cannabis moves toward Schedule III, Big Pharma prepares to reshape the industry. What it means for patients, access, and Arizona operators.

PFAS contamination in cannabis and hemp presents serious health and legal risks. Here's what growers and regulators need to know to protect patients and consumers.

Texas has expanded its medical marijuana law to include chronic pain, TBI, Crohn’s, and more—a major shift in patient access and cannabis policy.

As adult-use cannabis spreads across the U.S., medical marijuana programs are in decline—posing serious implications for patients and providers.

A misconfigured 323 GB database exposed nearly 1 million medical cannabis patient records—names, SSNs, IDs, and health data—in July 2025.